ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2019 Results - Earnings Call Transcript

LYON, France and CAMBRIDGE, Mass. , March  16, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells,  today announced the appointment of Melanie Rolli, M.D.,  to its Board of Directors and the intention to propose the ratification of her appointment at ERYTECH’s next General Meeting of Shareholders. Dr. Rolli has more than 15 years of experience in the global biopharmaceutical and biotechnology industry, including in both Europe and the United States. Dr. Rolli’s appointment follows the resignation of Allene Diaz, who resigned from the Board effective September 30, 2019.

ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors

Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers

Monthly information related to total number of voting rights and shares composing the share capital – February 29, 2020

Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics

ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service

Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2020

As of late, it has definitely been a great time to be an investor ERYTECH Pharma.

Will ERYTECH Pharma Continue to Surge Higher?

Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2019

Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019

First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors

ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q3 2019 Results - Earnings Call Transcript

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019

LYON, France and CAMBRIDGE, Mass., Nov.  04, 2019  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.

ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer

Artikel 223-16 der allgemeinen Bestimmungen der französischen Autorité des Marchés Financiers Artikel 223-16 der allgemeinen Bestimmungen der französischen Autorité des Marchés Financiers

Monatliches Informationsschreiben zu der Gesamtzahl von Stimmrechten und Aktien, aus denen sich das Aktienkapital zusammensetzt – 30. September 2019

Articolo 223-16 del regolamento generale dell’Autorité des Marchés Financiers francese Articolo 223-16 del regolamento generale dell’Autorité des Marchés Financiers francese

Informazioni mensili relative al numero totale dei diritti di voto e delle azioni che compongono il capitale sociale – lunedì 30 settembre 2019

Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019

Telefonkonferenz und Webcast am Mittwoch, 18. September um 14:30 Uhr MEZ / 8:30 Uhr EDT

ERYTECH veröffentlicht Business Update und gibt die Finanzergebnisse für das erste Halbjahr 2019 bekannt

Teleconferenza e webcast mercoledì 18 settembre ore 14:30 CET/8:30 am EDT

ERYTECH presenta business update e risultati finanziari del primo semestre del 2019

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2019 Results - Earnings Call Transcript

Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

LYON, Frankreich, Sept.  12, 2019  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP-Nasdaq: ERYP), ein biopharmazeutisches Unternehmen im klinischen Stadium, das innovative Therapien entwickelt, indem es therapeutische Wirkstoffe in roten Blutkörperchen einkapselt, hat heute bekanntgegeben, dass es am Mittwoch, dem 18. September 2019, um 14:30 Uhr MESZ (8:30 Uhr EST) eine Telefonkonferenz zum ersten Quartal und einen Webcast organisieren wird, um die operativen Highlights zu besprechen.

ERYTECH wird Gastgeber einer Telefonkonferenz zum zweiten Quartal 2019 und zum Business-Update sein

LIONE, Francia, Sept.  12, 2019  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), un’azienda biofarmaceutica in fase clinica che sviluppa terapie innovative incapsulando sostanze farmacologiche all'interno dei globuli rossi, ha annunciato oggi che ospiterà la teleconferenza e il webcast del secondo trimestre 2019 di mercoledì 18 settembre 2019 alle 14.30 CEST/8.30 AM EST per discutere i principali dati economici.

ERYTECH ospiterà la teleconferenza e il business update relativi del secondo trimestre 2019

Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2019 Results - Earnings Call Transcript

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)